Display options
Cite
Rastrelli M, Alaibac M, Stramare R, et al. Melanoma m (zero): diagnosis and therapy. ISRN Dermatol. 2013;2013:616170doi: 10.1155/2013/616170.
Rastrelli, M., Alaibac, M., Stramare, R., Chiarion Sileni, V., Montesco, M. C., Vecchiato, A., Campana, L. G., & Rossi, C. R. (2013). Melanoma m (zero): diagnosis and therapy. ISRN dermatology, 2013616170. https://doi.org/10.1155/2013/616170
Rastrelli, Marco, et al. "Melanoma m (zero): diagnosis and therapy." ISRN dermatology vol. 2013 (2013): 616170. doi: https://doi.org/10.1155/2013/616170
Rastrelli M, Alaibac M, Stramare R, Chiarion Sileni V, Montesco MC, Vecchiato A, Campana LG, Rossi CR. Melanoma m (zero): diagnosis and therapy. ISRN Dermatol. 2013 Apr 11;2013:616170. doi: 10.1155/2013/616170. Print 2013. PMID: 23691346; PMCID: PMC3649440.
Copy Download .nbib Format: NLM
Share it on

ISRN Dermatol. 2013 Apr 11;2013:616170. doi: 10.1155/2013/616170. Print 2013.

Melanoma m (zero): diagnosis and therapy.

ISRN dermatology

Marco Rastrelli, Mauro Alaibac, Roberto Stramare, Vanna Chiarion Sileni, Maria Cristina Montesco, Antonella Vecchiato, Luca Giovanni Campana, Carlo Riccardo Rossi

Affiliations

  1. Melanoma and Sarcoma Unit, Veneto Institute of Oncology, IOV IRCCS, 35128 Padua, Italy.

PMID: 23691346 PMCID: PMC3649440 DOI: 10.1155/2013/616170

Abstract

This paper reviews the epidemiology, diagnosis, and treatment of M zero cutaneous melanoma including the most recent developments. This review also examined the main risk factors for melanoma. Tumor thickness measured according to Breslow, mitotic rate, ulceration, and growth phase has the greatest predictive value for survival and metastasis. Wide excision of the primary tumor is the only potentially curative treatment for primary melanoma. The sentinel node biopsy must be performed on all patients who have a primary melanoma with a Breslow thickness > 1 mm, or if the melanoma is from 0,75 mm to 1 mm thick but it is ulcerated and/or the mitotic index is ≥1. Total lymph node dissection consists in removing the residual lymph nodes in patients with positive sentinel node biopsy, or found positive on needle aspiration biopsy, without radiological evidence of spread. Isolated limb perfusion and isolated limb infusion are employed in patients within transit metastases with a rate of complete remission in around 50% and 38% of cases. Electrochemotherapy is mainly indicated for palliation in cases of metastatic disease, though it may sometimes be useful to complete isolated limb perfusion. The only agent found to affect survival as an adjuvant treatment is interferon alpha-2. Adjuvant radiotherapy improves local control of melanoma in patients at a high risk of recurrence after lymph node dissection.

References

  1. CA Cancer J Clin. 2010 Sep-Oct;60(5):301-16 - PubMed
  2. J Surg Oncol. 2009 Aug 1;100(2):169-77 - PubMed
  3. J Clin Aesthet Dermatol. 2009 Oct;2(10):34-6 - PubMed
  4. Lancet. 2008 Jul 12;372(9633):117-26 - PubMed
  5. Exp Dermatol. 2010 Mar;19(3):233-9 - PubMed
  6. Eur J Cancer. 2009 Nov;45(17):3054-63 - PubMed
  7. J Am Acad Dermatol. 2011 Nov;65(5):1032-47 - PubMed
  8. Expert Rev Anticancer Ther. 2011 Nov;11(11):1693-701 - PubMed
  9. Genes Dev. 2012 Jun 1;26(11):1131-55 - PubMed
  10. World J Surg. 2011 Jul;35(7):1567-72 - PubMed
  11. Surgery. 2011 Jul;150(1):83-90 - PubMed
  12. J Natl Cancer Inst. 2010 Apr 7;102(7):493-501 - PubMed
  13. J Natl Cancer Inst. 2011 Dec 7;103(23):1771-7 - PubMed
  14. Cancer Causes Control. 2005 Oct;16(8):893-9 - PubMed
  15. Ann Surg. 2005 Sep;242(3):302-11; discussion 311-3 - PubMed
  16. Cancer. 2009 Feb 15;115(4):869-79 - PubMed
  17. Ann Surg. 2009 Mar;249(3):473-80 - PubMed
  18. Cell Mol Life Sci. 2012 May;69(9):1475-91 - PubMed
  19. Eur J Cancer. 2010 Jan;46(2):270-83 - PubMed
  20. Arch Dermatol. 2010 Mar;146(3):234-9 - PubMed
  21. Int J Cancer. 2008 Jun 15;122(12):2753-60 - PubMed
  22. Cancer J. 2012 Mar-Apr;18(2):176-84 - PubMed
  23. Cutis. 2012 May;89(5):208-11 - PubMed
  24. Melanoma Res. 2009 Jun;19(3):125-34 - PubMed
  25. Clin Dermatol. 2010 May-Jun;28(3):275-80 - PubMed
  26. J Am Acad Dermatol. 2012 Jan;66(1):37-45 - PubMed
  27. Br J Surg. 2012 Jun;99(6):821-30 - PubMed
  28. Cancer J. 2012 Mar-Apr;18(2):124-31 - PubMed
  29. Br J Dermatol. 2007 Jun;156(6):1287-94 - PubMed
  30. J Dermatol. 2012 Mar;39(3):290-4 - PubMed
  31. Int J Clin Oncol. 2008 Feb;13(1):33-41 - PubMed
  32. J Clin Oncol. 2006 Jun 20;24(18):2858-65 - PubMed
  33. Clin Dermatol. 2010 May-Jun;28(3):316-8 - PubMed
  34. Cochrane Database Syst Rev. 2009 Oct 07;(4):CD004835 - PubMed
  35. BMJ. 1990 Nov 3;301(6759):1005-6 - PubMed
  36. G Ital Dermatol Venereol. 2012 Feb;147(1):1-19 - PubMed
  37. Ann Surg Oncol. 2010 Nov;17(11):3000-7 - PubMed
  38. J Am Acad Dermatol. 2003 May;48(5):679-93 - PubMed
  39. Prog Biophys Mol Biol. 2011 Dec;107(3):362-6 - PubMed
  40. Lancet. 2011 Nov 5;378(9803):1635-42 - PubMed
  41. J Am Acad Dermatol. 2007 May;56(5):803-10 - PubMed
  42. Br J Dermatol. 2010 Aug;163(2):238-56 - PubMed
  43. Cancer J. 2012 Mar-Apr;18(2):203-7 - PubMed
  44. Ann Oncol. 2009 Aug;20 Suppl 6:vi1-7 - PubMed
  45. Curr Opin Oncol. 2011 Mar;23(2):183-8 - PubMed

Publication Types